The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation on how its legislation and regulatory processes would be impacted by a no-deal Brexit.
California-based clinical stage pharmaceutical company Recardio has halted its UK activities due to concerns over Brexit and how it will impact the approval of medicines.
Medical research group Recardio has reportedly halted a trial of an experimental heart drug because of uncertainties surrounding the UK’s departure from the European Union.